"Rewiring brain immunity: targeting microglial metabolism for neuroprotection in neurodegenerative disorders"

Mustafa M Shokr1

  • 1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Sinai University - Arish Branch, Arish, 45511, Egypt. mostafa.mohsen@su.edu.eg.

Metabolic Brain Disease
|November 25, 2025
PubMed

Insights

Microglia metabolism dictates brain inflammation in neurological diseases. Targeting microglial bioenergetics offers new therapies for neurodegenerative disorders by rebalancing immune responses and promoting neuroprotection.

Area of Science:

  • Neuroscience
  • Immunology
  • Metabolism

Background:

  • Neuroinflammation is central to neurological diseases, driven by microglia phenotypes.
  • Microglial metabolic repolarization controls their functional shifts between neuroprotection and neurotoxicity.

Purpose of the Study:

  • To review microglial metabolic phenotypes and their regulation.
  • To explore therapeutic strategies targeting microglial metabolism for neurodegenerative diseases.

Main Methods:

  • Synthesis of current research on microglial metabolism.
  • Discussion of metabolic sensors (AMPK, mTOR, HIF-1α) in disease contexts.
  • Review of therapeutic interventions impacting microglial metabolism.

Main Results:

  • Distinct metabolic profiles exist for pro-inflammatory (glycolytic) and anti-inflammatory (oxidative phosphorylation) microglia.
  • Metabolic sensors regulate these phenotypes in Alzheimer's, Parkinson's, MS, stroke, and TBI.
  • Pharmacological, nutritional, and microbiota-based strategies can modulate microglial metabolism.

Conclusions:

  • Targeting microglial bioenergetics presents a novel therapeutic avenue.
  • Re-tuning microglial metabolism can counteract neuroinflammation and enhance neuroprotection.
  • This approach holds promise for developing new disease-modifying therapies for neurodegenerative disorders.

Related Concept Videos

The Blood-brain Barrier00:49

The Blood-brain Barrier

Overview
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Gut-Brain Axis01:22

Gut-Brain Axis

The gut–brain axis is a bidirectional communication system that connects the gastrointestinal tract and the brain. This interaction is mediated through multiple pathways, including the vagus nerve, hormonal signals, immune responses, and chemical messengers produced by gut microbes.Microbial Contributions to Brain FunctionGut microbiota contributes significantly to brain function by producing neuroactive compounds. These include neuroactive compounds that influence neurotransmitters such as...